Home
Kaken Pharmaceutical

Kaken Pharmaceutical Market Share Analysis for July 2026

科研製薬株式会社のお問い合わせです。

Health > Biotechnology and Pharmaceuticals

Domainkaken.co.jp

Year Founded1982

Employees1001 - 5000

Annual Revenue$500M - $1B

Kaken Pharmaceutical

Kaken Pharmaceutical (including company regionals)

kaken.co.jp

See more website traffic and engagement information

Kaken Pharmaceutical Revenue up to July 2026 is 500M - 1B

revenue generated by Kaken Pharmaceutical top domains

Kaken Pharmaceutical top domains revenue over 3 years

Revenue for Kaken Pharmaceutical top domains

kaken.co.jp500M - 1B

See more with Sales Intelligence

Total visits to Kaken Pharmaceutical's top domains

Understand Kaken Pharmaceutical market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kaken.co.jp73.3K

See more with Sales Intelligence

Avg. visit duration in Kaken Pharmaceutical's top domains

Analyze Kaken Pharmaceutical engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kaken.co.jp00:01:14

See more with Sales Intelligence

Avg. pageviews on Kaken Pharmaceutical's top domains

See how Kaken Pharmaceutical keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kaken.co.jp2.00

See more with Sales Intelligence

Kaken Pharmaceutical top competitors by domain

Top similar sites in July 2026, ranked by their affinity

fuso-pharm.co.jpCompany NameFuso Pharmaceutical IndustriesEmployees1001 - 5000HQJapan, OsakaAnnual revenue$200M - $500MTotal visits80.4KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Kaken Pharmaceutical

These are the website technologies, by industry, used by Kaken Pharmaceutical top domains

Payment & Currencies (22)

PayPal

Advertising (3)

Google Adsense

Mobile (2)

Meta Viewport

Audio Video Media (1)

YouTube

More Technologies

5

See all

News & Signals from Kaken Pharmaceutical

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKaken Pharmaceutical Co.,Ltd acquired ARTham Therapeutics for $78M on Dec 1st '21.The drug was originally developed by Intellikine, which was acquired by Takeda in 2011, and Kaken acquired rights to the drug in December 2021 via a $78 million buyout of ARTham Therapeutics, a Takeda spinout.

NewsWhitehawk Therapeutics, Inc. sold assets to Kaken Pharmaceutical Co.,Ltd in the amount of $100M on Dec 31st '24.Whitehawk Therapeutics is a clinical-stage oncology company focused on ADCs after undergoing a complete strategic transformation in late 2024, divesting its Fyarro (nab-sirolimus) commercial business to Japan-based Kaken Pharmaceuticals for USD 100 million and simultaneously in-licensing a three-asset ADC portfolio from WuXi Biologics under an exclusive global development and commercialization agreement.

NewsAstria Therapeutics, Inc. partners with Kaken Pharmaceutical Co.,Ltd.Astria Therapeutics has entered an exclusive licensing agreement with Kaken Pharmaceutical for the development and commercialisation rights of navenibart in Japan.